1.Identification of a Novel Intronic Transcript Containing 11q13.5 HERV-W gag Sequence
Tianjin Medical Journal 2010;38(1):1-3
Objective:To identify the novel intronic transcripts containing 11q13.5 HERV-W gag sequence, and explore the modulation of the transcripts on the alternative splicing of host gene PTD015. Methods:Half-nested PCR and touchdown PCR were used to amplify the target transcripts. The transcripts were cloned and sequenced. The plasmids inserted with the target transcripts were transfected into JEG3 cells and the alternative spliced mRNA levels of PTD015 were measured with real time PCR. Results:A 1 739 bp novel intronic transcript containing 755 bp 11q13.5 HERV-W gag sequence, 527 bp 5′ long terminal repeat and 457 bp sequence on the 5′-end of 11q13.5 HERV-W was identified. The intronic antisense transcripts significantly down-regulated the alternative spliced mRNA levels of PTD015. Conclusion:The intronic antisense transcripts originating from the second intron of gene PTD015 could modulate the alternative splicing of the host gene PTD015.
2.Diagnosis and treatment of cholelithiasis complicated with abdominal tumors:a report of 36 caseas
Chunlin XIA ; Yueqing ZHU ; Yuanrong WANG ; Cunxiang ZOU
Chinese Journal of General Surgery 2001;0(08):-
Objective To study the causes of mis diagnosis and the experience of diagnosis and management for cholelithiasis complicated with abdominal tumors.Methods Clinical data of 36 cases of cholelithiasis complicated with abdominal tumors were analyzed retrospectively.Among them,24 were male,12 female.The age ranged from 48 to 82 year old.Each case was diagnosis as cholelithiasis and admitted to our hospital.Results In 36 patients,18 was diagnosed as complecated with abdominal tumors preoperatively;12 was diagnosed intraoperatively,while in 6 cases the tumor was misdiagmosed for 5 days to 3 months,finally the tumor was comfirmed by reoperation and pathology.Among the 36 cases,the tumors cluding 5 of carcinoma of gallbladder(13.9%),4 of cholangiocarcinoma(11.1%),3 of hepatoma(8.3%),6 of pancreatic carcinoma(16.7%),6 of gastric carcinoma(16.7%),7 of colon carcinoma(19.4%),2 of rectal carcinoma(5.5%).Of them,2 cases refused operation,2 cases underwent intervention operation,the others reseived operation.During primary operation,radical resection of the tumor and cholecystectomy and/or common bile duct(CBD) exploration was performed in 18 patients,palliation resection and cholecystectomy and/or CBD exploration performed in 4 patients,exploratory laparotomy performed in 4 patients,and only LC and/or CBD exploration performed in 6 patients.Of the latters,reoperation was performed 5 days to 3 months after primary operation.4 patients had tumor radical resection,1 had palliation resection,and 1 had interventional therapy.Conclusions Cholelithiasis may complicated with abdominal tumor,especially with digestive tract tumor.For cholelithiasis patient the history-taking need to be done carefully before operation.For the senile patient and the patient without typical symptoms or physical signs,the systems checking shoud be done carefully preoperatively,and abdominal cavity should be checked carefully intraoperatvely to find the tumor,which may exist in abdominal cavity.the patient with syndrome of post-cholecystectomy shoud be carefully followed up to avoid the mis diagnosis and mistreatment of the tumor.
3.Chinese expert consensus for non-antiinfective effects and clinical use of macrolides
Jiangtao LIN ; Yongming ZHANG ; Changzheng WANG ; Xin ZHOU ; Mao HUANG ; Chuntao LIU ; Changgui WU ; Huanying WAN ; Wencheng YU ; Yuanrong DAI
Chinese Journal of Internal Medicine 2017;56(7):546-557
Important/potential value of macrolides has been proved in the management of chronic respiratory diseases by increasing basic and clinical trials.Through three face-to-face discussions,10 experts examined important data and drafted this consensus related to macrolides:(1) mechanism of nonantiinfective effects;(2) clinical use in chronic respiratory diseases;(3) cautions of long-term use.The mechanism out of non-antiinfective effects includes anti-inflammatory effect,modifying airway secretion,immune-regulation related to antibacterial effect,corticoid saving effect and anti-viral effect.The efficacy of long-term use of low-dose macrolides is definitely confirmed in diffuse panbronchiolitis,chronic rhinosinusitis.It is considerably used in bronchiectasia,cystic fibrosis,severe asthma and chronic obstructive pulmonary disease.Further studies should be conducted in cryptogenic organizing pneumonia and respiratory viral infection.It should be paid attention to its possible adverse effects (including drug interactions,cardiac toxicity,ototoxicity and disturbance of intestinal flora) and drug resistance in long-term use.A Chinese consensus for non-antiinfective effects and clinical use of macrolides is developed for the first time,which aims to expand their rational use and the further research.
4.Chinese expert consensus on the surgical treatment of primary palmar hyperhidrosis (2021 version)
Yanguo LIU ; Wenhan WENG ; Yuanrong TU ; Jun WANG
Chinese Medical Journal 2022;135(11):1264-1271
Primary palmar hyperhidrosis (PPH) is a pathologic condition of excessive sweating on hands that has adverse impacts on patients' social activity, professional life, and psychological state. Endoscopic thoracic sympathicotomy (ETS) is by far the treatment choice for PPH with the most stable and durable curative effects, but special attention should be given to the side effects of the surgery, especially compensatory hyperhidrosis (CH). This consensus is the second version of the Chinese Expert Consensus on the Surgical Treatment of PPH by the China Expert Committee on Palmar Hyperhidrosis (CECPH), which was published 10 years ago. This consensus emphasizes the need for special attention and careful assessment of the patients’ feelings, as well as their emotional and mental state, and emphasizes that distress due to palmar sweating and the desire for treatment are prerequisites for diagnosis. It also provides a more nuanced delineation of CH and reviews all new attempts to prevent and treat this side effect. New evidence of the epidemiology, pathogenesis of PPH, and indications for surgery were also assessed or recommended.
5.Recent advances in combined central and peripheral demyelination
Chinese Journal of Neuromedicine 2017;16(9):966-969
Combined central and peripheral demyelination (CCPD) refers to the demyelmation concurrently or sequentially occuring in the central and peripheral nervous systems.CCPD is a new disease entity,which is different from the independent central or peripheral nervous system demyelination.The pathogenesis of CCPD is unclear.The immune abnormalities may be involved.CCPD has low incidence,various manifestations,no specific biomarkers,and no uniform diagnostic criteria.This review summarizes the etiology,pathogenesis,clinical features,specific biomarkers,imaging characteristics,treatments and prognoses of CCPD to improve our understanding of CCPD.
6.Wedge tissue resection combined with pterygoid flap for nipple reduction and shortening
Qianqian ZHANG ; Yi HOU ; Huizhen HUANG ; Shiruo ZHANG ; Yuanrong YOU ; Hao WANG
Chinese Journal of Plastic Surgery 2021;37(7):752-756
Objective:To explore the clinical effect of a new method for nipple reduction and shortening in nipple hypertrophy.Methods:A retrospective analysis was made with patients with nipple hypertrophy who were admitted to Shanghai Mylike Medical Cosmetic Hospital from January 2018 to December 2019. The optimal size of the postoperative nipple was determined according to the patient’s requirements at the un-erectile state. Two wedge-shaped tissues resection were designed at the two symmetrical edges of the nipple to determine the diameter of the new nipple, and two dual wing shaped flaps were designed at the top of the nipple to determine the height of the new nipple. After local anesthesia, the redundant skin and subcutaneous tissue were cut off, and the corresponding points were closed and sutured. The appearance of the nipple was observed after operation. The nipple sensation and erectile function were evaluated by touching the nipple with cotton swab.Results:A total of 22 patients with nipple hypertrophy, aged from 24 to 35 years old, were female patients after childbirth and lactation. No wound nonunion or infection occurred. The blood supply and sensation of the nipple were good, and the shape of the nipple was significantly improved. All patients were followed up for 3-9 months, and the nipple sensation and erectile function recovered completely. All patients were satisfied with the postoperative result.Conclusions:The reduction of nipple by wedge tissue resection and wing flap can correct both the diameter and height of the nipple, while the nipple sensation and erection function are not affected. The procedure is easily performed with satisfactory result.
7.Wedge tissue resection combined with pterygoid flap for nipple reduction and shortening
Qianqian ZHANG ; Yi HOU ; Huizhen HUANG ; Shiruo ZHANG ; Yuanrong YOU ; Hao WANG
Chinese Journal of Plastic Surgery 2021;37(7):752-756
Objective:To explore the clinical effect of a new method for nipple reduction and shortening in nipple hypertrophy.Methods:A retrospective analysis was made with patients with nipple hypertrophy who were admitted to Shanghai Mylike Medical Cosmetic Hospital from January 2018 to December 2019. The optimal size of the postoperative nipple was determined according to the patient’s requirements at the un-erectile state. Two wedge-shaped tissues resection were designed at the two symmetrical edges of the nipple to determine the diameter of the new nipple, and two dual wing shaped flaps were designed at the top of the nipple to determine the height of the new nipple. After local anesthesia, the redundant skin and subcutaneous tissue were cut off, and the corresponding points were closed and sutured. The appearance of the nipple was observed after operation. The nipple sensation and erectile function were evaluated by touching the nipple with cotton swab.Results:A total of 22 patients with nipple hypertrophy, aged from 24 to 35 years old, were female patients after childbirth and lactation. No wound nonunion or infection occurred. The blood supply and sensation of the nipple were good, and the shape of the nipple was significantly improved. All patients were followed up for 3-9 months, and the nipple sensation and erectile function recovered completely. All patients were satisfied with the postoperative result.Conclusions:The reduction of nipple by wedge tissue resection and wing flap can correct both the diameter and height of the nipple, while the nipple sensation and erection function are not affected. The procedure is easily performed with satisfactory result.
8.Chest CT Imaging Features of Indeterminate Pulmonary Nodules and Outcomes in Patients with High-grade Soft Tissue Sarcoma: A Single-center Retrospective Study
Yuanrong WANG ; Liming ZHANG ; Daji SONAM ; Yan ZHU ; Gentao FAN ; Yicun WANG ; Xin SHI ; Sujia WU ; Guangxin ZHOU
Cancer Research on Prevention and Treatment 2024;51(2):99-103
Objective To explore the imaging features, clinical outcome, and prognosis of indeterminate pulmonary nodules (IPN) in patients with high-grade soft tissue sarcoma. Methods A retrospective study of 82 patients with high-grade soft tissue sarcoma who have IPNs. The clinical characteristics, imaging features of IPN, and survival of patients were analyzed with statistical software. Results The IPN size of 82 patients was 6.453±0.864 mm. IPN diameter, shape, density, and nodule discovery interval may be CT imaging features related to malignancy tendency. Age (
9.Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients.
Jinwan WANG ; Yan SUN ; Yongyu LIU ; Qitao YU ; Yiping ZHANG ; Kai LI ; Yunzhong ZHU ; Qinghua ZHOU ; Mei HOU ; Zhongzhen GUAN ; Weilian LI ; Wu ZHUANG ; Donglin WANG ; Houjie LIANG ; Fengzhan QIN ; Huishan LU ; Xiaoqing LIU ; Hong SUN ; Yanjun ZHANG ; Jiejun WANG ; Suxia LUO ; Ruihe YANG ; Yuanrong TU ; Xiuwen WANG ; Shuping SONG ; Jingmin ZHOU ; Lifen YOU ; Jing WANG ; Chen YAO
Chinese Journal of Lung Cancer 2005;8(4):283-290
BACKGROUNDEndostar™ (rh-endostatin, YH-16) is a new recombinant human endostatin developed by Medgenn Bioengineering Co. Ltd., Yantai, Shandong, P.R.China. Pre-clinical study indicated that YH-16 could inhibit tumor endothelial cell proliferation, angiogenesis and tumor growth. Phase I and phase II studies revealed that YH-16 was effective as single agent with good tolerance in clinical use.The current study was to compare the response rate , median ti me to progression (TTP) ,clinical benefit andsafety in patients with advanced non-small cell lung cancer ( NSCLC) , who were treated with YH-16 plus vi-norelbine and cisplatin (NP) or placebo plus NP.
METHODSFour hundred and ninety-three histologically or cy-tologically confirmed stage IIIB and IV NSCLC patients , withlife expectancy > 3 months and ECOG perform-ance status 0-2 , were enrolledin a randomized ,double-blind ,placebo-controlled , multicenter trial ,either trialgroup : NP plus YH-16 (vinorelbine 25 mg/m² on day 1 and day 5 ,cisplatin 30mg/m² on days 2 to 4 , YH-167.5mg/m² on days 1 to 14) or control group : NP plus placebo (vinorelbine 25 mg/m² on day 1 and day 5 ,cis-platin 30 mg/m² on days 2 to 4 ,0.9% sodium-chloride 3 .75 ml on days 1 to 14) every 3 weeks for 2-6 cycles .The trial endpoints included response rate ,clinical benefit rate ,time to progression,quality of life and safety .
RESULTSOf 486 assessable patients , overall response rate was 35.4% in trial group and 19.5% in controlgroup (P=0 .0003) . The median TTP was 6 .3 months and 3 .6 months for trial group and control group respectively (P < 0 .001) . The clinical benefit rate was 73 .3 %in trial group and 64.0% in control group (P=0 .035) .In untreated patients of trial group and control group ,the response rate was 40 .0% and 23.9%(P=0 .003) ,the clinical benefit rate was 76 .5 % and 65 .0 % (P=0 .023) ,the median TTP was 6 .6 and 3 .7months (P=0 .0000) ,respectively .In pretreated patients of trial group and control group ,the response ratewas 23.9% and 8.5%(P=0 .034) ,the clinical benefit rate was 65.2% and 61.7%(P=0 .68) ,the median TTP was 5 .7 and 3 .2 months (P=0 .0002) ,respectively . The relief rate of clinical symptoms in trial groupwas higher than that of those in control group ,but no significance existed (P > 0 .05) . The score of quality oflife in trial group was significantly higher than that in control group (P=0 .0155) after treatment . There were no significant differences in incidence of hematologic and non-hematologic toxicity , moderate and severe sideeffects betweentrial group and control group .
CONCLUSIONSThe addition of YH-16 to NP regimen results in significantly and clinically meaningful improvement in response rate , median time to tumor progression,and clinical benefit rate compared with NP alone in advanced NSCLC patients . YH-16 in combination with chemotherapy shows a synergic activity and a favorable toxic profile in advanced cancer patients .
10.Clinical treatment guideline for pulmonary blast injury (version 2023)
Zhiming SONG ; Junhua GUO ; Jianming CHEN ; Jing ZHONG ; Yan DOU ; Jiarong MENG ; Guomin ZHANG ; Guodong LIU ; Huaping LIANG ; Hezhong CHEN ; Shuogui XU ; Yufeng ZHANG ; Zhinong WANG ; Daixing ZHONG ; Tao JIANG ; Zhiqiang XUE ; Feihu ZHOU ; Zhixin LIANG ; Yang LIU ; Xu WU ; Kaican CAI ; Yi SHEN ; Yong SONG ; Xiaoli YUAN ; Enwu XU ; Yifeng ZHENG ; Shumin WANG ; Erping XI ; Shengsheng YANG ; Wenke CAI ; Yu CHEN ; Qingxin LI ; Zhiqiang ZOU ; Chang SU ; Hongwei SHANG ; Jiangxing XU ; Yongjing LIU ; Qianjin WANG ; Xiaodong WEI ; Guoan XU ; Gaofeng LIU ; Junhui LUO ; Qinghua LI ; Bin SONG ; Ming GUO ; Chen HUANG ; Xunyu XU ; Yuanrong TU ; Liling ZHENG ; Mingke DUAN ; Renping WAN ; Tengbo YU ; Hai YU ; Yanmei ZHAO ; Yuping WEI ; Jin ZHANG ; Hua GUO ; Jianxin JIANG ; Lianyang ZHANG ; Yunfeng YI
Chinese Journal of Trauma 2023;39(12):1057-1069
Pulmonary blast injury has become the main type of trauma in modern warfare, characterized by externally mild injuries but internally severe injuries, rapid disease progression, and a high rate of early death. The injury is complicated in clinical practice, often with multiple and compound injuries. Currently, there is a lack of effective protective materials, accurate injury detection instrument and portable monitoring and transportation equipment, standardized clinical treatment guidelines in various medical centers, and evidence-based guidelines at home and abroad, resulting in a high mortality in clinlcal practice. Therefore, the Trauma Branch of Chinese Medical Association and the Editorial Committee of Chinese Journal of Trauma organized military and civilian experts in related fields such as thoracic surgery and traumatic surgery to jointly develop the Clinical treatment guideline for pulmonary blast injury ( version 2023) by combining evidence for effectiveness and clinical first-line treatment experience. This guideline provided 16 recommended opinions surrounding definition, characteristics, pre-hospital diagnosis and treatment, and in-hospital treatment of pulmonary blast injury, hoping to provide a basis for the clinical treatment in hospitals at different levels.